SG11202105913RA - Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) - Google Patents
Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)Info
- Publication number
- SG11202105913RA SG11202105913RA SG11202105913RA SG11202105913RA SG11202105913RA SG 11202105913R A SG11202105913R A SG 11202105913RA SG 11202105913R A SG11202105913R A SG 11202105913RA SG 11202105913R A SG11202105913R A SG 11202105913RA SG 11202105913R A SG11202105913R A SG 11202105913RA
- Authority
- SG
- Singapore
- Prior art keywords
- usp19
- inhibitors
- pharmaceutical compounds
- specific protease
- ubiquitin specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1819937.2A GB201819937D0 (en) | 2018-12-06 | 2018-12-06 | Pharmaceutical compounds |
| GBGB1904339.7A GB201904339D0 (en) | 2019-03-28 | 2019-03-28 | Pharmaceutical compounds |
| GBGB1911311.7A GB201911311D0 (en) | 2019-08-07 | 2019-08-07 | Pharmaceutical compounds |
| PCT/GB2019/053457 WO2020115501A1 (en) | 2018-12-06 | 2019-12-06 | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105913RA true SG11202105913RA (en) | 2021-07-29 |
Family
ID=68887435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105913RA SG11202105913RA (en) | 2018-12-06 | 2019-12-06 | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220033397A1 (en) |
| EP (1) | EP3890829A1 (en) |
| JP (1) | JP2022512128A (en) |
| KR (1) | KR20210102285A (en) |
| CN (1) | CN113365696A (en) |
| AU (1) | AU2019393162A1 (en) |
| BR (1) | BR112021010644A2 (en) |
| CA (1) | CA3121376A1 (en) |
| IL (1) | IL283706A (en) |
| MX (1) | MX2021006540A (en) |
| SG (1) | SG11202105913RA (en) |
| WO (1) | WO2020115501A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
| GB202104097D0 (en) | 2021-03-24 | 2021-05-05 | Almac Discovery Ltd | Pharmaceutical compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO111096A0 (en) * | 1996-07-18 | 1996-08-08 | Fujisawa Pharmaceutical Co., Ltd. | New compound |
| WO2003029209A2 (en) | 2001-10-02 | 2003-04-10 | Smithkline Beecham Corporation | Chemical compounds |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| TWI698436B (en) * | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors |
| MA41291A (en) * | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER |
| WO2016126926A1 (en) * | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
| EP3253759A1 (en) * | 2015-02-05 | 2017-12-13 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
| JP2018504431A (en) * | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス，インコーポレイテッド | Thienopyrimidinone as a ubiquitin-specific protease 7 inhibitor |
| HUE048590T2 (en) * | 2016-06-10 | 2020-08-28 | Servier Lab | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them |
| FR3052452B1 (en) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | NOVEL PIPERIDINYL DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| GB201612938D0 (en) * | 2016-07-26 | 2016-09-07 | Almac Discovery Ltd | Pharmaceutical compounds |
| GB201801562D0 (en) * | 2018-01-31 | 2018-03-14 | Almac Diagnostics Ltd | Pharmaceutical compounds |
-
2019
- 2019-12-06 AU AU2019393162A patent/AU2019393162A1/en not_active Abandoned
- 2019-12-06 SG SG11202105913RA patent/SG11202105913RA/en unknown
- 2019-12-06 CA CA3121376A patent/CA3121376A1/en active Pending
- 2019-12-06 WO PCT/GB2019/053457 patent/WO2020115501A1/en unknown
- 2019-12-06 CN CN201980090768.3A patent/CN113365696A/en active Pending
- 2019-12-06 JP JP2021532111A patent/JP2022512128A/en active Pending
- 2019-12-06 US US17/299,959 patent/US20220033397A1/en active Pending
- 2019-12-06 MX MX2021006540A patent/MX2021006540A/en unknown
- 2019-12-06 KR KR1020217020079A patent/KR20210102285A/en active Search and Examination
- 2019-12-06 EP EP19821176.5A patent/EP3890829A1/en active Pending
- 2019-12-06 BR BR112021010644-8A patent/BR112021010644A2/en not_active Application Discontinuation
-
2021
- 2021-06-03 IL IL283706A patent/IL283706A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3121376A1 (en) | 2020-06-11 |
| WO2020115501A1 (en) | 2020-06-11 |
| US20220033397A1 (en) | 2022-02-03 |
| JP2022512128A (en) | 2022-02-02 |
| AU2019393162A1 (en) | 2021-06-17 |
| CN113365696A (en) | 2021-09-07 |
| KR20210102285A (en) | 2021-08-19 |
| EP3890829A1 (en) | 2021-10-13 |
| MX2021006540A (en) | 2021-07-07 |
| BR112021010644A2 (en) | 2021-09-28 |
| IL283706A (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284050A (en) | Substituted pyrazolopyrimes and substituted purines and their use as ubiquitin specific-processing protease 1 (usp1) inhibitors | |
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| EP3116859A4 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
| MX2019001011A (en) | Pharmaceutical compounds. | |
| ZA202004909B (en) | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19) | |
| IL279397A (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL283706A (en) | Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19) | |
| PH12018500504A1 (en) | Compounds useful for inhibiting ror-gamma-t | |
| EP3749365A4 (en) | Peptidyl inhibitors of calcineurin-nfat interaction | |
| DK3911304T3 (en) | MODIFIED-RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS | |
| IL281357B (en) | Cd73 inhibitors and pharmaceutical uses thereof | |
| IL280770A (en) | Diazabicyclooctanones as inhibitors of serine beta-lactamases | |
| IL274737A (en) | New piperidinyl derivatives as inhibitors of ubiquitin specific protease 7 | |
| MX2021003643A (en) | Terpinoid derivatives and uses thereof. | |
| IL281451A (en) | Uses of plasminogen activator inhibitor 1 (pai-1) inhibitors | |
| EP4034130A4 (en) | Pharmaceutical compounds and methods of use | |
| TR201620309A2 (en) | Pharmaceutical compositions of metformin hydrochloride and pioglitazone hydrochloride | |
| IL307163A (en) | Pharmaceutical compounds as inhibitors of ubiquitin specific protease 19 (usp19) | |
| ZA202005459B (en) | Methods of use and pharmaceutical compositions of a selective syk inhibitor | |
| EP3737945A4 (en) | Novel use of kirrel2 and kirrel2 inhibitor | |
| EP3844289A4 (en) | Composition and use of cas protein inhibitors | |
| PT3833665T (en) | Diazabicyclooctanones as inhibitors of serine beta-lactamases | |
| GB201817343D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| GB201817344D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| SI3638686T1 (en) | Peptidyl ketoamides as inhibitors of rohomboid proteases |